Prevalence of Malignancies in Patients With Primary Aldosteronism.
Prevalence of Malignancies in Patients With Primary Aldosteronism.
复制标题
原发性醛固酮增多症患者的恶性肿瘤患病率。
DOI:
--
复制
发表时间:
2016
影响因子:
5.8
通讯作者:
S. Hahner
中科院分区:
文献类型:
--
作者:
K. Lang;K. Weber;M. Quinkler;A. Dietz;H. Wallaschofski;A. Hannemann;N. Friedrichs;L. Rump;Britta Heinze;C. Fuss;I. Quack;H. Willenberg;M. Reincke;B. Allolio;S. Hahner
CONTEXT
Primary aldosteronism (PA) is the most common cause of secondary hypertension. Aldosterone excess can cause DNA damage in vitro and in vivo. Single case reports have indicated a coincidence of PA with renal cell carcinoma and other tumors. However, the prevalence of benign and malignant neoplasms in patients with PA has not yet been studied.
PATIENTS AND DESIGN
In the multicenter MEPHISTO study, the prevalence of benign and malignant tumors was investigated in 335 patients with confirmed PA. Matched hypertensive subjects from the population-based Study of Health in Pomerania cohort served as controls.
RESULTS
Of the 335 PA patients, 119 (35.5%) had been diagnosed with a tumor at any time, and 30 had two or more neoplasms. Lifetime malignancy occurrence was reported in 9.6% of PA patients compared to 6.0% of hypertensive controls (P = .08). PA patients with a history of malignancy had higher baseline aldosterone levels at diagnosis of PA (P = .009), and a strong association between aldosterone levels and the prevalence of malignancies was observed (P = .03). In total, 157 neoplasms were identified in the PA patients; they were benign in 61% and malignant in 25% of the cases (14% of unknown dignity). Renal cell carcinoma was diagnosed in five patients (13% of all malignancies) and was not reported in controls
CONCLUSION
Compared to hypertensive controls, the prevalence of malignancies was positively correlated with aldosterone levels, tended to be higher in PA patients, but did not differ significantly.